GlassScriptPhysician profile
Sean Green
NPI 1902850936
$5,654.26
in general payments reported to CMS, 2019-2025
43 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,614 · 2022: $1,696 · 2023: $1,395 · 2024: $725 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.29 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,278.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $744.91 | 2021-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $576.27 | 2021-2025 | |
| Lilly USA, LLC | $341.53 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $275.62 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $249.07 | 2021-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.93 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.63 | 2021-2023 | Trulance, Xifaxan |
| Pfizer INC. | $151.62 | 2021-2025 | |
| Abbott Laboratories | $133.79 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Novartis Pharmaceuticals Corporation | $130.74 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $128.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $111.79 | 2022-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $104.72 | 2021 | |
| Merck Sharp & Dohme LLC | $103.40 | 2021-2023 | Pneumovax 23, Gardasil 9, Vaxneuvance |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.